Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome

Pediatric Nephrology

Volumn 26, Issue 8, 2011, Pages 1255-1261

  Aizawa Yashiro, Tomomi ^a   Tsuruga, Kazushi ^a   Watanabe, Shojiro ^a   Oki, Eishin ^a   Ito, Etsuro ^a   Tanaka, Hiroshi ^a,b  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Cyclosporine intolerant; Cyclosporineresistant; Mizoribine; Multidrug therapy; Refractory nephrotic syndrome; Tacrolimus

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; CYCLOSPORINE INTOLERANT REFRACTORY NEPHROTIC SYNDROME; CYCLOSPORINE RESISTANT REFRACTORY NEPHROTIC SYNDROME; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; MORNING DOSAGE; NEPHROTIC SYNDROME; NEPHROTOXICITY; OUTCOME ASSESSMENT; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; STEROID DEPENDENT RELAPSING NEPHROTIC SYNDROME; STEROID RESISTANT NEPHROTIC SYNDROME; TREATMENT DURATION;

ADOLESCENT; CHILD; CYCLOSPORINE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROTIC SYNDROME; PILOT PROJECTS; PREDNISONE; RIBONUCLEOSIDES; TACROLIMUS; YOUNG ADULT;

EID: 80052456186     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-011-1876-z     Document Type: Article

References (25)

1. Hino S, Takemura T, Okada M, Murakami K, Yagi K, Fukushim K, Yoshioka K (1998) Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis 31:932-939.
2. Inoue Y, Iijima K, Nakamura H, Yoshikawa N (1999) Two-year cyclosporine treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 13:33-38. (Pubitemid 29206255)
3. El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahamad N, Sobh M (2005) Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant 20:2433-2438. (Pubitemid 41548868)
4. Hamasaki Y, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Yata N, Kaneko T, Honda M (2009) Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 24:2177-2185.
5. Suzuki K, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito E, Tanaka H (2010) Benefits of once-daily administration of cyclosporine A for children with steroid-dependent, relapsing nephrotic syndrome. Tohoku J Exp Med 220:183-186.
6. Bhimma R, Adhikari M, Asharam K, Connolly C (2006) Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 26:544-551. (Pubitemid 46143876)
7. Suzuki K, Tsugawa K, Tanaka H (2006) Tacrolimus for the treatment of focal segmental glomerulosclerosis resistant to cyclosporine A. Pediatr Nephrol 21:1913-1914. (Pubitemid 44741174)
8. Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP (2008) Tacrolimus: a new therapy steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 23:910-913. (Pubitemid 351767558)
9. Butani L, Ramsamooj R (2009) Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 24:1517-1523.
10. Roberti I, Vyas S (2010) Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 25:1117-1124.
11. Cattran DC, Wang MM, Appel G, Matalon A, Briggs W (2004) Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 62:405-411. (Pubitemid 39654577)
12. Okada M, Sigimoto K, Yagi K, Yanagida H, Tabata N, Takemura T (2007) Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int 49:933-937. (Pubitemid 350197148)
13. Oki E, Tsuruga K, Kudo M, Tsugawa K, Suzuki K, Tanaka H (2009) A novel multidrug therapy for difficult cyclosporineresistant focal segmental glomerulosclerosis. Pediatr Nephrol 24:773-775.
14. Ballarin J, Poveda R, Ara J, Perez L, Calero C, Grinyo JM, Romero R (2007) Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant 22:3196-3201. (Pubitemid 350202550)
15. International Study of Kidney Disease in Children (1981) The primary nephrotic syndrome in children: identification of patients with minimal change nephrotic syndrome from initial response to prednisone: a report of the International Study of Kidney Disease in Children. J Pediatr 98:561-564.
16. Takeda A, Horike K, Onoda H, Ohtsuka Y, Yoshida A, Uchida K, Morozumi K (2007) Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile. Nephrology (Carlton) 12:197- 204. (Pubitemid 46426861)
17. Schwartz GJ (1992) Does kL/Pcr estimate GFR, or does GFR determine k? Pediatr Nephrol 6:512-515.
18. Tanaka H, Oki E, Tsuruga K, Yashiro T, Hanada I, Ito E (2009) Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. Clin Nephrol 72:430-436.
19. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S (2000) A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 58:317-324. (Pubitemid 30429877)
20. Honda M (2002) Nephrotic syndrome and mizoribine in children. Pediatr Int 44:210-216. (Pubitemid 34225271)
21. Shimizu H, Takahashi M, Takeda S, Tahara K, Inoue S, Nakamata Y, Kaneko T, Takeyoshi I, Morishita Y, Kobayashi E (2003) Effect of conversion from cyclosporine A to mizoribine on transplant arteriosclerosis in rat aortic allograft models. Microsurgery 23:454-457. (Pubitemid 37314987)
22. Hara S, Umino D, Someya T, Fujinaga S, Ohtomo Y, Murakami H, Shimizu T (2009) Protective effects of mizoribine on cyclosporine A nephropathy in rats. Pediatr Res 66:524-527.
23. Takeuchi S, Hiromura K, Tomioka M, Takahashi S, Sakairi T, Maeshima A, Kaneko Y, Kuroiwa T, Nojima Y (2010) The immunosuppressive drug mizoribine directory prevents podocyte injury in puromycin aminosucleoside nephrosis. Nephron Exp Nephrol 116:e3-e10.
24. Tanaka H, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito Y, Sato N, Kawasaki Y, Suzuki J (2010) Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis. Clin Rheumatol 29:1049-1054.
25. Lanata CM, Mahmood T, Fine DM, Petri M (2010) Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 19:935-94.